IQVIA Holdings Inc. filings document a NYSE-listed operating company with common stock under the IQV symbol and a business centered on clinical research services, commercial insights and healthcare intelligence. Form 8-K reports document quarterly and annual operating results, segment disclosures for R&D Solutions and Commercial Solutions, share repurchase authorizations and amendments to the company's credit agreement.
Proxy and governance filings describe annual meeting matters, director elections and appointments, executive compensation, equity incentive plans and stockholder voting items. The filings also provide formal records of capital-structure terms, material agreements and board oversight for IQVIA's life sciences and healthcare services business.
IQVIA Holdings Inc. reports first-quarter 2026 results with revenues of $4,151 million, up 8.4% from 2025. Net income attributable to IQVIA rose to $274 million, and diluted earnings per share increased to $1.61 from $1.40.
Commercial Solutions revenue grew to $1,754 million, while Research & Development Solutions reached $2,397 million. Operating cash flow was strong at $618 million, supporting capital spending, acquisitions and $552 million of share repurchases. Total debt stood at $15,908 million with access to additional revolving credit capacity.
IQVIA Holdings Inc. reported strong first-quarter 2026 results, with revenue of $4,151 million, up 8.4% year-over-year, driven by both Commercial and R&D Solutions. Commercial Solutions revenue grew 11.6% to $1,754 million, while Research & Development Solutions reached $2,397 million, up 6.2%.
GAAP net income was $274 million with diluted EPS of $1.61. Adjusted EBITDA rose to $932 million, and Adjusted Diluted EPS increased to $2.90, up 7.4% year-over-year. Free Cash Flow was $491 million, up 15% and equal to 100% of Adjusted Net Income.
R&D Solutions contracted backlog was $34.2 billion, with about $8.9 billion expected to convert to revenue in the next twelve months and a book-to-bill of 1.04x. The company repurchased $552 million of stock and reaffirmed 2026 revenue and Adjusted EBITDA guidance while raising Adjusted Diluted EPS guidance to $12.65–$12.95.
IQVIA Holdings Inc Schedule 13G filing shows Vanguard Capital Management reports beneficial ownership of 12,714,783 shares of Common Stock as of 03/31/2026. The stake represents 7.49% of the class and Vanguard reports sole dispositive power over those shares.
The filing lists 1,687,800 shares as sole voting power and affirms holdings are reported on behalf of Vanguard affiliates and managed funds. The form is signed 04/30/2026 by Ashley Grim.
Stamps Sheila A reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Sheila A. Stamps received a grant of 1,571 deferred shares linked to common stock as compensation. The award is priced at $160.68 per deferred share and increases her directly held deferred share balance to 4,210.
Each deferred share is convertible into one share of IQVIA common stock upon settlement. Under the company’s Non-Employee Director Deferral Plan, the deferred shares become settleable when she ceases to be a director, upon a change in control of the company, or upon her death, with no expiry date.
Wims Morris Leslie reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Morris Leslie Wims received a compensation grant of 1,571 deferred shares on common stock. These deferred shares are convertible into an equal number of IQVIA common shares upon settlement under the company’s Non-Employee Director Deferral Plan.
The award increased the director’s directly held deferred share balance to 6,465. The deferred shares become settleable when the director ceases to serve on the board, upon a change in control of the company, or upon the director’s death, and they do not have an expiry date.
Kaelin William G Jr reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director William G. Kaelin Jr. received a grant of 1,571 deferred shares on April 23, 2026. Each deferred share represents the right to receive one share of IQVIA common stock upon settlement under the company’s Non-Employee Director Deferral Plan.
The deferred shares become settleable when he ceases to be a director, upon a change in control of the company, or upon his death. After this award, he beneficially holds 1,571 deferred shares directly, with no stated expiry date on the award.
LEONARD JOHN M reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director John M. Leonard reported receiving an equity award of 1,571 shares of common stock on April 23, 2026. The shares were granted as compensation for his role as a non-employee director and are fully vested upon grant, with no purchase price paid. Following this award, Leonard directly holds 16,946 shares of IQVIA common stock.
GOGGINS COLLEEN A reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Colleen A. Goggins received an award of 1,571 shares of common stock on April 23, 2026. The shares were granted as compensation for Non-Employee Directors and are fully vested upon grant, bringing her direct holdings to 14,453 shares.
Fasano Jim reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Jim Fasano received a grant of 1,571 deferred shares, each linked to one share of common stock. These deferred shares settle when he ceases to be a director, upon a change in control of the company, or upon his death. Following this award, he holds 5,845 deferred shares in total.
IQVIA HOLDINGS INC. director John G. Danhakl reported an indirect acquisition of 1,571 shares of common stock on an award that was fully vested upon grant for Non-Employee Directors. These shares are held in the Danhakl Revocable Family Trust.
Following the award, the trust holds 30,612 shares of IQVIA common stock, and a related LLC controlled by the trust holds an additional 1,275 shares. The filing reflects compensation-related grants and indirect holdings, not open-market purchases or sales.